Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × MCRC × tislelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 25 Carcinoma, Hepatocellular 22 Colorectal Neoplasms 16 Stomach Neoplasms 13 Esophageal Squamous Cell Carcinoma 13 Esophageal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Lung Neoplasms 8 Head and Neck Neoplasms 8 Cholangiocarcinoma 7 Uterine Cervical Neoplasms 6 Triple Negative Breast Neoplasms 6 Small Cell Lung Carcinoma 6 Nasopharyngeal Carcinoma 6 Rectal Neoplasms 5 Recurrence 4 Pancreatic Neoplasms 4 Locally Advanced Rectal Cancer 4 Hodgkin Disease 4 Colonic Neoplasms 4 Neoplasms 3 NSCLC 3 Lymphoma, Extranodal NK-T-Cell 3 Glioblastoma 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Melanoma 2 Lymphoma, Follicular 2

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡